Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2022 | $21.00 | In-Line → Outperform | Evercore ISI Group |
| 12/27/2021 | $24.68 | Buy → Neutral | HC Wainwright & Co. |
| 12/27/2021 | $29.00 → $25.00 | Overweight → Equal-Weight | Barclays |
| 12/23/2021 | Outperform → In-Line | Evercore ISI Group | |
| 10/4/2021 | $27.00 | Buy | Citigroup |
| 8/5/2021 | $27.00 → $30.00 | Buy | HC Wainwright & Co. |
| 8/5/2021 | $23.00 | Outperform | Credit Suisse |
| 7/13/2021 | $24.00 → $27.00 | Overweight | Barclays |
SC 13G - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)
SC 13G - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)
15-12B - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
8-K - Ortho Clinical Diagnostics Holdings plc (0001828443) (Filer)
25-NSE - Ortho Clinical Diagnostics Holdings plc (0001828443) (Subject)
Evercore ISI Group upgraded Ortho Clinical Diagnostic from In-Line to Outperform and set a new price target of $21.00
HC Wainwright & Co. downgraded Ortho Clinical Diagnostic from Buy to Neutral and set a new price target of $24.68
Barclays downgraded Ortho Clinical Diagnostic from Overweight to Equal-Weight and set a new price target of $25.00 from $29.00 previously
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Quidel Corporation (NASDAQ:QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc ("Ortho"), one of the world's larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the "Ortho Scheme Order")
Quidel Corporation (NASDAQ:QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc ("Ortho"), one of the world's larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the "Ortho Scheme Order"). The order will become effective once the Or
RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) ("Ortho" or the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ:QDEL) ("Quidel") pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the "BCA"). The closing of the transactions contemplated by the BCA is subject to sanction of the combination by the High Court of Justice of England and W
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
4 - Ortho Clinical Diagnostics Holdings plc (0001828443) (Issuer)
RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022. Ortho Clinical Diagnostics will hold a conference call the same day at 4:30 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the call. Thos
Highlights • Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in constant currency and 15.7% excluding CoV-2 assay sales • Fourth quarter Operating income was $31.1 million, while Adjusted EBITDA was $127.9 million • Fiscal year Operating income was $173.9 million, while Adjusted EBITDA was $548.1 million, up 20.2% year-over-year RARITAN, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial
Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4%Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022. The Company is providing these updates in advance of its presentation at the J.P. Morgan Healthcare Conference on January 11, 2022. Selected Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results (Unaudit